Literature DB >> 11966511

Prospective audit of gastroscopy under the 'three-day rule': a regional initiative in Italy to reduce waiting time for suspected malignancy.

F Parente1, S Bargiggia, G Bianchi Porro.   

Abstract

BACKGROUND: A regional initiative, called the 'three-day rule', has recently been introduced in Italy to facilitate the earlier diagnosis of malignancy. It requires patients with suspected severe diseases to have a diagnostic procedure performed within three working days of referral by a general practitioner. AIM: To assess prospectively the effectiveness and compliance with the three-day rule for upper digestive malignancies.
METHODS: We compared patients referred for gastroscopy under the three-day rule initiative with contemporaneous open access referrals over a 12-month period at a single large teaching hospital in west Milan. We compared the prevalence of malignancies and other serious non-neoplastic diseases as well as the waiting times in the two groups. The appropriateness of the indications for each referral was also reviewed by a gastroenterologist blind to the outcome of the test.
RESULTS: One hundred and forty-two patients referred for gastroscopy under the three-day rule scheme and 767 routine referrals were studied. Significantly more oesophageal/gastric cancers (6% vs. 1%) and serious benign gastrointestinal lesions (grade II-III oesophagitis or peptic ulcer) were diagnosed in three-day rule patients in comparison with routine referrals (P < 0.05). The rate of inappropriate referral was significantly lower in the three-day rule group than in the open access group (39% vs. 22%) (P < 0.01). The estimated cost of the three-day rule scheme (in extra list examinations alone) was 10 780 euros, with about 1198 euros per diagnosis of cancer, but only 229.5 euros per 'useful' diagnosis (including peptic ulcer disease and oesophagitis).
CONCLUSIONS: Significantly more upper gastrointestinal cancers and serious benign diseases can be found within a short period to comply with the three-day rule scheme. However, some general practitioners appear to over-interpret alarm symptoms, leading to some inappropriate referrals. Better awareness of appropriate urgent referral criteria is needed in order to ensure that the best use is made of the resources available.

Entities:  

Mesh:

Year:  2002        PMID: 11966511     DOI: 10.1046/j.1365-2036.2002.01241.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  5 in total

Review 1.  Gastroenterology services in the UK. The burden of disease, and the organisation and delivery of services for gastrointestinal and liver disorders: a review of the evidence.

Authors:  J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams
Journal:  Gut       Date:  2007-02       Impact factor: 23.059

2.  Usefulness of a fast track list for anxious patients in a upper GI endoscopy.

Authors:  Fabrizio Cardin; Alessandra Andreotti; Manuel Zorzi; Claudio Terranova; Bruno Martella; Bruno Amato; Carmelo Militello
Journal:  BMC Surg       Date:  2012-11-15       Impact factor: 2.102

3.  Appropriateness and diagnostic yield of upper gastrointestinal endoscopy in an open-access endoscopy system.

Authors:  Abdulrahman M Aljebreen; Khalid Alswat; Majid A Almadi
Journal:  Saudi J Gastroenterol       Date:  2013 Sep-Oct       Impact factor: 2.485

4.  Appropriateness of Upper Gastrointestinal Endoscopy: Will the Diagnostic Yield Improve by the use of American Society of Gastroenterology Guidelines?

Authors:  Muazzam Tahir
Journal:  Euroasian J Hepatogastroenterol       Date:  2016-12-01

5.  Improvement in appropriateness and diagnostic yield of fast-track endoscopy during the COVID-19 pandemic in Northern Italy.

Authors:  Gianpiero Manes; Simone Saibeni; Lucienne Pellegrini; Desiree Picascia; Fabio Pace; Mario Schettino; Cristina Bezzio; Germana de Nucci; Cesare Hassan; Alessandro Repici
Journal:  Endoscopy       Date:  2020-11-04       Impact factor: 9.776

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.